Trial Outcomes & Findings for Does Fluid Requirement Decrease With the Use of Pneumatic Compression Device on Lower Limbs (NCT NCT03789474)

Results Overview

heart rate monitoring at T0

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

60 participants

Primary outcome timeframe

15 minutes pre induction

Results posted on

2020-08-21

Participant Flow

The study was conducted from January 2017 to July 2018 at ALL INDIA INSTITUTE OF MEDICAL SCIENCES,RISHIKESH,UTTARAKHAND ,INDIA.

Participant milestones

Participant milestones
Measure	Group A No intervention was done ,served as a control group.	Group B Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Overall Study STARTED	30	30
Overall Study COMPLETED	30	30
Overall Study NOT COMPLETED	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900	Total n=60 Participants Total of all reporting groups
Age, Continuous	36.4 years STANDARD_DEVIATION 9.4 • n=30 Participants	34.1 years STANDARD_DEVIATION 7.6 • n=30 Participants	35.2 years STANDARD_DEVIATION 8.5 • n=60 Participants
Sex: Female, Male Female	19 Participants n=30 Participants	18 Participants n=30 Participants	37 Participants n=60 Participants
Sex: Female, Male Male	11 Participants n=30 Participants	12 Participants n=30 Participants	23 Participants n=60 Participants
Race and Ethnicity Not Collected	—	—	0 Participants Race and Ethnicity were not collected from any participant.
Height	1.62 meters STANDARD_DEVIATION .1 • n=30 Participants	1.59 meters STANDARD_DEVIATION .1 • n=30 Participants	1.60 meters STANDARD_DEVIATION .1 • n=60 Participants
Weight	60.77 kilograms STANDARD_DEVIATION 8.73 • n=30 Participants	62.13 kilograms STANDARD_DEVIATION 9.1 • n=30 Participants	61.45 kilograms STANDARD_DEVIATION 8.91 • n=60 Participants
Body Mass Index (BMI)	22.8 kg^m2 STANDARD_DEVIATION 3.74 • n=30 Participants	24.5 kg^m2 STANDARD_DEVIATION 4.2 • n=30 Participants	23.65 kg^m2 STANDARD_DEVIATION 3.97 • n=60 Participants

PRIMARY outcome

Timeframe: 15 minutes pre induction

heart rate monitoring at T0

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Heart Rate at T0	85.23 beats per minute Standard Deviation 17.81	88.833 beats per minute Standard Deviation 18.28

PRIMARY outcome

Timeframe: post induction heart rate

heart rate monitoring at T1

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Heart Rate at T1	79.60 beats per minute Standard Deviation 16.44	88.13 beats per minute Standard Deviation 18.35

PRIMARY outcome

Timeframe: 15 minutes after induction

heart rate monitoring at T2

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Heart Rate at T2	79.97 beats per minute Standard Deviation 13.26	88.57 beats per minute Standard Deviation 20.30

PRIMARY outcome

Timeframe: 30 minutes after induction

heart rate monitoring at T3

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Heart Rate at T3	76.70 beats per minute Standard Deviation 12.26	84.77 beats per minute Standard Deviation 16.80

PRIMARY outcome

Timeframe: 60 minutes after induction

heart rate monitoring at T4

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Heart Rate at T4	77.40 beats per minute Standard Deviation 10.93	83.56 beats per minute Standard Deviation 14.83

PRIMARY outcome

Timeframe: 120 minutes after induction

heart rate monitoring at T5

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Heart Rate at T5	77.53 beats per minute Standard Deviation 12.71	82.17 beats per minute Standard Deviation 14.22

PRIMARY outcome

Timeframe: post operative period after 30 min in post anaesthesia care unit

heart rate monitoring at T6

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Heart Rate at T6	85.06 beats per minute Standard Deviation 12.58	88.23 beats per minute Standard Deviation 13.87

PRIMARY outcome

Timeframe: 15 min before induction

systolic blood pressure measurement at T0

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Systolic Blood Pressure at T0	119.06 millimeters of mercury Standard Deviation 11.71	122.1 millimeters of mercury Standard Deviation 16.01

PRIMARY outcome

Timeframe: post induction

systolic blood pressure measurement at T1

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Systolic Blood Pressure at T1	102.33 millimeters of mercury Standard Deviation 15.31	106.80 millimeters of mercury Standard Deviation 14.82

PRIMARY outcome

Timeframe: 15 min after induction

systolic blood pressure measurement at T2

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Systolic Blood Pressure at T2	100.73 millimeters of mercury Standard Deviation 12.12	106.93 millimeters of mercury Standard Deviation 13.45

PRIMARY outcome

Timeframe: 30 min after induction

systolic blood pressure measurement at T3

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Systolic Blood Pressure at T3	106.23 millimeters of mercury Standard Deviation 15.08	109.90 millimeters of mercury Standard Deviation 12.93

PRIMARY outcome

Timeframe: 60 min after induction

systolic blood pressure measurement at T4

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Systolic Blood Pressure at T4	111.10 millimeters of mercury Standard Deviation 15.59	111.23 millimeters of mercury Standard Deviation 12.45

PRIMARY outcome

Timeframe: 120 min after induction

systolic blood pressure measurement at T5

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Systolic Blood Pressure at T5	108.86 millimeters of mercury Standard Deviation 10.92	115.70 millimeters of mercury Standard Deviation 12.79

PRIMARY outcome

Timeframe: post operative period 30 min in post asnaesthesia care unit

systolic blood pressure measurement at T6

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Systolic Blood Pressure at T6	118.80 millimeters of mercury Standard Deviation 10.34	126.03 millimeters of mercury Standard Deviation 10.49

PRIMARY outcome

Timeframe: 15 minutes before induction

Diastolic blood pressure measurement at T0

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Diastolic Blood Presure at T0	76.00 millimeters of mercury Standard Deviation 11.66	72.23 millimeters of mercury Standard Deviation 13.30

PRIMARY outcome

Timeframe: immediately after induction

Diastolic blood pressure measurement at T1

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Diastolic Blood Pressure at T1	66.30 millimeters of mercury Standard Deviation 12.93	69.33 millimeters of mercury Standard Deviation 11.96

PRIMARY outcome

Timeframe: 15 minutes after induction

Diastolic blood pressure measurement at T2

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Diastolic Blood Pressure at T2	65.37 millimeters of mercury Standard Deviation 11.66	66.53 millimeters of mercury Standard Deviation 12.29

PRIMARY outcome

Timeframe: 30 minutes after induction

Diastolic blood pressure measurement at T3

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Diastolic Blood Pressure at T3	69.46 millimeters of mercury Standard Deviation 15.42	68.13 millimeters of mercury Standard Deviation 12.15

PRIMARY outcome

Timeframe: 60 minutes after induction

Diastolic blood pressure measurement at T4

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Diastolic Blood Pressure at T4	69.36 millimeters of mercury Standard Deviation 16.75	69.16 millimeters of mercury Standard Deviation 10.56

PRIMARY outcome

Timeframe: 120 minutes after induction

Diastolic blood pressure measurement at T5

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Diastolic Blood Pressure at T5	66.63 millimeters of mercury Standard Deviation 11.53	70.80 millimeters of mercury Standard Deviation 9.93

PRIMARY outcome

Timeframe: post induction 30 min in post anaesthesia care unit

Diastolic blood pressure measurement at T6

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Diastolic Blood Pressure at T6	70.66 millimeters of mercury Standard Deviation 9.80	75.80 millimeters of mercury Standard Deviation 8.58

PRIMARY outcome

Timeframe: 15 minutes pre induction

Mean blood pressure measurement at T0

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Mean Blood Pressure at T0	90.04 millimeters of mercury Standard Deviation 11.03	92.19 millimeters of mercury Standard Deviation 13.43

PRIMARY outcome

Timeframe: immediately after induction

Mean blood pressure measurement at T1

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Mean Blood Pressure at T1	78.38 millimeters of mercury Standard Deviation 13.29	81.82 millimeters of mercury Standard Deviation 11.89

PRIMARY outcome

Timeframe: 15 minutes after induction

Mean blood pressure measurement at T2

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Mean Blood Pressure at T2	77.38 millimeters of mercury Standard Deviation 11.46	79.99 millimeters of mercury Standard Deviation 11.41

PRIMARY outcome

Timeframe: 30 minutes after induction

Mean blood pressure measurement at T3

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Mean Blood Pressure at T3	82.42 millimeters of mercury Standard Deviation 14.36	82.05 millimeters of mercury Standard Deviation 11.57

PRIMARY outcome

Timeframe: 60 minutes after induction

Mean blood pressure measurement at T4

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Mean Blood Pressure at T4	83.55 millimeters of mercury Standard Deviation 15.79	83.19 millimeters of mercury Standard Deviation 10.14

PRIMARY outcome

Timeframe: 120 minutes after induction

Mean blood pressure measurement at T5

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Mean Blood Pressure at T5	81.16 millimeters of mercury Standard Deviation 10.64	85.76 millimeters of mercury Standard Deviation 9.78

PRIMARY outcome

Timeframe: post operative 30 min in post anaesthesia care unit

Mean blood pressure measurement at T6

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Mean Blood Pressure at T6	86.71 millimeters of mercury Standard Deviation 8.98	92.54 millimeters of mercury Standard Deviation 8.27

PRIMARY outcome

Timeframe: 15 minutes pre induction

Femoral vein velocity measuement at T0

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Femoral Vein Velocity at T0	29.35 centimeters per second Standard Deviation 4.20	31.31 centimeters per second Standard Deviation 7.28

PRIMARY outcome

Timeframe: 15 minutes after induction

Femoral vein velocity measurement at T2

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Femoral Vein Velocity at T2	27.79 centimeters per second Standard Deviation 4.02	33.61 centimeters per second Standard Deviation 7.61

PRIMARY outcome

Timeframe: after 30 minutes in post anaesthesia care unit

Femoral vein velocity measurement at T6

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Femoral Vein Velocity at T6	28.35 centimeters per second Standard Deviation 5.64	31.92 centimeters per second Standard Deviation 5.96

PRIMARY outcome

Timeframe: 15 minutes pre induction to 30 minutes in post anaesthesia care unit

the variance in femoral vein velocity was calculated by subtracting the femoral vein velocity pre induction from femoral vein velocity 15 min after induction divided by mean of the two values in percentage

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Femoral Vein Velocity Variance	-5.419 percentage of velocity Standard Deviation 8.444	7.188 percentage of velocity Standard Deviation 5.385

PRIMARY outcome

Timeframe: 15 minutes pre induction

Femoral artery velocity measurement at T0

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Femoral Artery Velocity at T0	69.15 centimeters per second Standard Deviation 14.08	76.25 centimeters per second Standard Deviation 13.39

PRIMARY outcome

Timeframe: 15 minutes after induction

Femoral artery velocity measurement at T2

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Femoral Artery Velocity at T2	67.74 centimeters per second Standard Deviation 11.96	73.91 centimeters per second Standard Deviation 11.62

PRIMARY outcome

Timeframe: after 30 minutes in post anaesthesia care unit

Femoral artery velocity measurement at T6

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Femoral Artery Velocity at T6	69.82 centimeters per second Standard Deviation 11.78	76.63 centimeters per second Standard Deviation 14.07

PRIMARY outcome

Timeframe: 15 min pre induction

inferior venacava diameter (maximum) meaurement at T0

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Inferior Venacava Diameter (Maximum) at T0	1.16 centimeters Standard Deviation 0.14	1.26 centimeters Standard Deviation 0.17

PRIMARY outcome

Timeframe: 15 min after induction

inferior venacava diameter (maximum) meaurement at T2

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Inferior Venacava Diameter (Maximum) at T2	1.27 centimeters Standard Deviation 0.11	1.27 centimeters Standard Deviation 0.17

PRIMARY outcome

Timeframe: after 30 min in post anaesthesia care unit

inferior venacava diameter (maximum) meaurement at T6

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Inferior Venacava Diameter (Maximum) at T6	1.19 centimeters Standard Deviation 0.13	1.31 centimeters Standard Deviation 0.17

PRIMARY outcome

Timeframe: 15 min pre induction

inferior venacava diameter (minimum) meaurement at T0

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Inferior Venacava Diameter (Minimum) at T0	1.06 centimeters Standard Deviation 0.13	1.15 centimeters Standard Deviation 0.15

PRIMARY outcome

Timeframe: 15 min after induction

inferior venacava diameter (minimum) meaurement at T2

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Inferior Venacava Diameter (Minimum) at T2	1.02 centimeters Standard Deviation 0.09	1.15 centimeters Standard Deviation 0.15

PRIMARY outcome

Timeframe: after 30 min in post anaesthesia care unit

inferior venacava diameter (minimum) meaurement at T6

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Inferior Venacava Diameter (Minimum) at T6	1.11 centimeters Standard Deviation 0.13	1.18 centimeters Standard Deviation 0.17

PRIMARY outcome

Timeframe: 15 min pre induction

the collapsibility index was calculated by dividing the difference of maximum inferior vena cava diameter and minimum inferior vena cava diameter by mean of the two diameters multiplied by 100.This was done for pre induction spontaneously breathing patients

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Inferior Venacava Diameter Collapsibility Index at T0	9.06 percentage of diameter Standard Deviation 4.17	9.32 percentage of diameter Standard Deviation 1.62

PRIMARY outcome

Timeframe: 15 min after induction

the inferior venacava distensibility index for post induction mechanically ventilated patients. It was calculated by dividing the difference of maximum inferior vena cava diameter and minimum inferior vena cava diameter by minimum inferior vena cava diameters multiplied by 100 .

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Inferior Venacava Diameter Distensibility Index at T2	11.05 percentage of diameter Standard Deviation 4.17	8.39 percentage of diameter Standard Deviation 2.841

PRIMARY outcome

Timeframe: after 30 minutes in post anaesthesia care unit

the collapsibility index was calculated by dividing the difference of maximum inferior vena cava diameter and minimum inferior vena cava diameter by mean of the two diameters multiplied by 100.This was done for pre induction spontaneously breathing patients

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Inferior Venacava Diameter Collapsibility Index at T6	7.04 percentage of diameter Standard Deviation 3.46	10.03 percentage of diameter Standard Deviation 4.10

PRIMARY outcome

Timeframe: operative period

Population: the population is same as the assigned population.

fluid requirement (cumulative) during the operative period.

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
FLUID REQUIREMENT (Cumulative)	1456.67 milliliters Standard Deviation 307.87	1291.66 milliliters Standard Deviation 320.04

PRIMARY outcome

Timeframe: During operating procedure

Total blood loss during operation

Outcome measures

Outcome measures
Measure	Group A n=30 Participants No intervention was done ,served as a control group.	Group B n=30 Participants Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used. HUNTLEIGH FLOWTRON ACS900
Blood Loss During Operation	99.67 milliliters Standard Deviation 50.34	116.67 milliliters Standard Deviation 41.80

Adverse Events

Group 1

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Group 2

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr M KESARI

ALL INDIA INSTITUTE OF MEDICAL SCIENCES,RISHIKESH,UTTARAKHAND,INDIA.

Phone: 7093005219

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place